Advertisement
Organisation › Details
Recursion Pharmaceuticals Inc. (Nasdaq: RXRX)
Recursion is a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation. Enabling its mission is the Recursion Operating System, a platform built across diverse technologies that continuously expands one of the world's largest proprietary biological and chemical datasets, the Recursion Data Universe. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset the Recursion Map, a collection of hundreds of billions of searchable inferences across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine. The Company is proudly headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life science industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. *
Start | 2013-01-01 established | |
Group | Recursion Pharmaceuticals (Group) | |
Industry | AI-based drug discovery / AI-based drug development | |
Industry 2 | artificial intelligence (AI) / machine learning (ML) | |
Person | Gibson, Chris (Recursion Pharmaceuticals 201907 CEO + Co-Founder) | |
Person 2 | Virani, Shafique (Recursion 202009 Chief Corp Development Officer formerly Roche Global Head Neuroscience Partnering) | |
Region | Salt Lake City, UT | |
Country | United States (USA) | |
Street | 41 South Rio Grande Street | |
City | 84101 Salt Lake City, UT | |
Tel | +1-385-269-0203 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | D: 101 to 500 (2021-02-17) |
Currency | USD | |
Annual sales | 3,962,000 (revenue, total, consolidated (2020) 2020-12-31) | |
Profit | -87,006,000 (2020-12-31) | |
Cash | 262,126,000 (2020-12-31) | |
* Document for »About Section«: Recursion Pharmaceuticals, Inc.. (12/7/21). "Press Release: Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Recursion Pharmaceuticals (Group)
- [1] Recursion Pharmaceuticals, Inc.. (12/7/21). "Press Release: Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening...
- [2] Recursion Pharmaceuticals, Inc.. (12/6/21). "Press Release: Recursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search Capabilities". Salt Lake City, UT....
- [3] Recursion Pharmaceuticals, Inc.. (9/9/20). "Press Release: Recursion Secures $239 Million in Equity Financing to Advance Technology-Enabled Drug Discovery Platform and Pipeline". Salt Lake City, UT....
- [4] Bayer AG. (9/9/20). "Press Release: Bayer Collaborates with Recursion to Strengthen Digital Drug Discovery and Advance New Therapies for Fibrotic Diseases". Berlin & Salt Lake City, UT....
- [5] Recursion Pharmaceuticals, Inc.. (7/15/19). "Press Release: Recursion Pharmaceuticals Secures $121 Million in Series C Financing". Salt Lake City, UT....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top